Speakers
Rupert Major
Rachel Marrington
Javeria Peracha
Alexandra Yates
Science & Education
Room: Grosvenor Room
This session was first presented at the UK Kidney associations National conference where it was well received by Renal colleagues- the session now comes to UK med lab.
It will overview:
The work led by the GIRFT initiated taskforce (GIRFT, UKNEQAS, UKAA and the ACB) on identifying unwarranted variation in AKI reporting and recommendations on how it should be standardised.
Presentations from key Renal physicians in the development and implementation of the NICE recommended KFRE for the monitoring of CKD.
Rupert Major 15:30 – 15:55 The Kidney Failure Risk Equation (KFRE)
Javeria Peracha 15:55 – 16:30 Systems Implementation of the Kidney Failure Risk Equation
Consultant Nephrologist, University Hospitals of Leicester, Leicester, UK
Honorary Associate Professor, Department of Cardiovascular Sciences, University of Leicester, Leicester, UK
Dr Rupert Major, PhD MBChB MRCP(UK) ESE(Neph), studied at the University of Leicester, qualifying as a medical doctor in 2009. Since then, he has pursued a combined clinical-academic career path including National Institute of Health Research academic training posts. His 2018 PhD, funded by Kidney Research UK, focused on cardiovascular risk prediction in chronic kidney disease. Dr Major has developed the Kidney Failure Risk Equation (KFRE) to predict the risk of needing dialysis or kidney transplantation for individuals with chronic kidney disease in the UK. In 2021 KFRE was recommended by NICE. He leads the UK Kidney Association’s KFRE implementation group. Dr Major has published in multiple leading kidney and general medical journals and has presented and received scientific awards at several international medical conferences for his research.
Senior Clinical Fellow - Renal Medicine
Dr. Javeria Peracha is a renal and general medicine trainee in the West Midlands. Her research interests include developing models of integrated chronic kidney disease (CKD) care that will help improve early detection and management of patients with CKD in the community. She is working with the UK Kidney Association Kidney Failure Risk Equation (KFRE) group to facilitate systems implementation of KFRE including within Laboratory Information Management Systems (LIMS).
Alexandra, is a Consultant Clinical scientist in the Clinical biochemistry department at the Countess of Chester hospital, GB, where her interest include analytical interferences, renal medicine, and quality improvement. Other wider interest include equality and diversity within healthcare organizations, Alexandra is passionate in enacting meaningful change leading to equity for all and recognizing the benefits this bring to the healthcare and wider community.
Alexandra was appointed as Director of Scientific affairs for the Association for clinical biochemistry and Laboratory medicine in May 2019 after 5 years on the scientific committee, and a previous role as a national member on the ACB council.
As chair of the Scientific and clinical practice committee, she leads the committee in the vision that; the scientific committee and clinical practice committee should serve all LabMed members across pan-pathology disciplines, enabling and promoting translation research and innovation, and providing scientific and clinical expertise to our strategic partners, benefiting the wider health care community.
Pronouns: She/her
Consultant Clinical Biochemist Lancashire Teaching Hospitals
Dr Myers is a consultant clinical biochemist at Lancashire Teaching Hospitals NHS Foundation Trust (LTH), Royal Preston Hospital, having previously been the associate divisionalmedical director for pathology for 4 years and clinical director of pathology for 14 years. Dr Myers is also the lead scientist for the trust. He chairs the trust Point of Care Testing Committee.
Dr Myers is the Senior Clinical Advisor on the NHS Getting it Right First Time (GIRFT) for Pathology, a member of the Device Expert Advisory Committee (DEAC), chair of the MHRA IVD Expert Advisory Group and Expert Advisor on the DHSC Technology Validation Group (TVG).
Dr Myers has taken a lead role in a continuousprogram of pathology redesign, improving the clinical and operational effectiveness of pathology delivery while improving productivity. His interests include the use of automation, point of care testing and informatics in improving the quality of the diagnostic process and redesigning a pathology delivery that is patient focussed. He has translated the “Laboratory Anywhere” concept to ensure that diagnostics is delivered in a variety of locations both inside and outside the hospital ensuring that diagnostics are embedded in the patient pathway, rather than remote from the patient. He is involved in several projects for the direct delivery of diagnostics to BAME communities and vulnerable groups in the community and worked with the NHSE chief scientific officer’s team on the delivery of point of care diagnostics in patients with learning difficulties and patients experiencing mental health issues. He has also been involved in translating NICE diagnostic recommendations into service delivery models.
Dr Myershas worked on many clinical pathways where the introduction of novel decision diagnostics has improved the patient pathway and resulted in reduction in total pathway costs.